Skip to main content
. 2013 Oct 1;6(5):528–538. doi: 10.1593/tlo.13367

Figure 6.

Figure 6

Assay LODs using model CTC samples. Varying levels of KRAS G13D mutation-positive tumor cells (MDA-MB-231) were spiked into healthy donor blood and processed on the IsoFlux System. gDNA was amplified, purified, and tested for KRAS mutations. The Ct difference between KRAS mutant and wild-type assays (dCt) was calculated. Samples having as few as nine recovered tumor cells were detectable using the qPCR assay. Healthy control samples remained above the mutation detection cutoff.